Form 4: Boston Scientific EVP Arthur Butcher Reports Stock Transactions

Arthur Butcher, EVP & Group President at Boston Scientific, reports the vesting and conversion of performance share units and a disposition of shares to cover tax obligations.

Summary

• Arthur Butcher, an Executive Vice President at Boston Scientific, reported transactions involving Boston Scientific common stock and performance share units.
• On January 1, 2025, Butcher converted 8,940 performance share units into common stock.
• Also on January 1, 2025, Butcher disposed of 4,416 shares of common stock at a price of $89.32.
• These shares were disposed of to cover tax obligations.
• Butcher also reported holding 13,367 shares indirectly through a 401(k) plan.
• Following these transactions, Butcher directly owns 5,502 shares of Boston Scientific common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions, which carries a neutral sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Boston Scientific.
• Similar filings are regularly made by executives at comparable companies such as Medtronic (MDT) and Abbott Laboratories (ABT).
• The vesting of performance share units is a typical component of executive compensation packages designed to align executive incentives with company performance, similar to practices observed at Johnson & Johnson (JNJ) and Stryker (SYK).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership by a company executive.
• The disposition of shares to cover tax obligations is a standard practice and is unlikely to significantly affect stakeholders.

Key Dates